The Markup You Never See: How the Traditional Pharmacy Supply Chain Inflates Your Prescription Costs

When you hand over your insurance card at a retail pharmacy counter, the transaction feels simple. You pay your copay, you collect your medication, you leave. What you do not see — and what the pharmacy industry has little incentive to make visible — is the layered financial architecture that determined what that copay actually was.

Behind every prescription dispensed at a traditional pharmacy lies a supply chain involving manufacturers, wholesalers, pharmacy benefit managers, insurers, and the pharmacy itself. Each party in that chain earns a margin. And in a system as opaque as American pharmaceutical distribution, those margins are rarely small.

Who Are Pharmacy Benefit Managers — And Why Do They Matter to Your Wallet?

To understand why prescription costs are higher than they need to be, it is necessary to understand pharmacy benefit managers, or PBMs. These largely unknown intermediaries sit between insurance companies and pharmacies, negotiating drug prices, processing claims, and determining which medications are covered under a given plan.

The three largest PBMs in the United States — CVS Caremark, Express Scripts, and OptumRx — collectively manage pharmacy benefits for the majority of insured Americans. Together, they wield enormous pricing power. Yet the way they profit is not always aligned with patient savings.

PBMs earn revenue through a practice known as spread pricing: charging insurance plans more for a drug than they reimburse the dispensing pharmacy, then retaining the difference. They also collect rebates from manufacturers in exchange for favorable formulary placement — rebates that, critics argue, incentivize the inclusion of higher-cost brand-name drugs over less expensive generic alternatives. A 2019 report by the Federal Trade Commission found that PBM practices contribute meaningfully to inflated drug costs for both insurers and patients, though the full extent of their impact remains a subject of ongoing regulatory scrutiny.

For the average patient, the practical consequence is a copay that reflects not the actual cost of producing or distributing a medication, but rather the outcome of a series of behind-the-scenes financial negotiations in which the patient had no seat at the table.

The Retail Pharmacy Overhead Problem

Independent of PBM dynamics, traditional brick-and-mortar pharmacies carry structural costs that direct-to-consumer models do not. Physical locations require commercial real estate, utilities, in-store staffing, and the operational infrastructure of a retail environment. These overhead expenses are, inevitably, embedded in the pricing of the products sold within them.

According to a 2023 analysis by the RAND Corporation, retail pharmacy dispensing costs average between $10 and $14 per prescription — costs that are either passed directly to consumers or absorbed into the pricing structures negotiated with PBMs and insurers. In either case, the patient ultimately bears the burden.

Home delivery pharmacy models operate with a fundamentally different cost structure. Without storefront overhead, high-traffic staffing requirements, or the inefficiencies of walk-in prescription management, direct-to-consumer pharmacy services can achieve lower per-prescription operating costs. Those savings can then be reflected in patient pricing.

Where the Savings Are Most Pronounced

Not every medication category offers equal savings through home delivery, but several stand out as areas where the cost differential is most significant.

Maintenance medications for chronic conditions — including treatments for hypertension, diabetes, high cholesterol, thyroid disorders, and depression — represent the clearest opportunity. These are drugs taken daily or weekly over months or years. At a retail pharmacy, patients typically pay a 30-day copay. Through home delivery, 90-day supplies are standard, often at a cost equivalent to two months' worth of the retail copay — effectively providing one month of medication at no additional charge.

Specialty medications, which treat conditions such as multiple sclerosis, rheumatoid arthritis, and certain cancers, represent another area of significant cost exposure. Retail specialty pharmacy markups can be substantial, and the supply chain for these drugs is particularly complex. Home delivery services that specialize in this category can often access manufacturer patient assistance programs and copay support more efficiently, reducing out-of-pocket costs for patients who qualify.

Generic medications, while already lower in cost than their brand-name counterparts, are subject to considerable price variation across pharmacy locations. A 2022 study published in JAMA Internal Medicine found that the price of a 30-day supply of a common generic could vary by as much as 447 percent across pharmacies within the same metropolitan area. Home delivery services that standardize generic pricing eliminate this variability and consistently offer rates at the lower end of the spectrum.

Real Numbers: What Patients Are Actually Saving

The abstract language of supply chain economics becomes considerably more concrete when translated into patient savings. A patient managing Type 2 diabetes with metformin, a statin, and a blood pressure medication might pay between $45 and $75 per month in copays at a retail pharmacy, depending on their plan. Through a home delivery service offering 90-day supplies at negotiated rates, the same three medications might cost $30 to $50 for a three-month period — a savings of more than 60 percent on an annualized basis.

For patients managing more complex regimens, the arithmetic becomes even more compelling. A 2021 report from the Employee Benefit Research Institute found that patients who switched from retail to mail-order pharmacy services for maintenance medications saved an average of $297 per year in out-of-pocket costs. For households managing multiple chronic conditions, savings frequently exceeded $600 annually.

Transparency as a Competitive Advantage

Beyond raw cost savings, home delivery pharmacy models offer something the traditional retail system rarely provides: pricing transparency. At MedDelivered, patients can review the cost of their medications before completing an order, with clear breakdowns of what their insurance covers and what their out-of-pocket responsibility will be. There are no surprise fees at the point of dispensing, no last-minute formulary substitutions, and no ambiguity about what a 90-day supply will cost compared to a 30-day one.

This transparency is not merely a convenience feature. In a healthcare system where unexpected medical costs remain the leading cause of personal bankruptcy in the United States, the ability to anticipate and plan for prescription expenses has genuine financial significance for American families.

Rethinking Where You Fill Your Prescriptions

The decision of where to fill a prescription has historically been driven by habit, proximity, or the path of least resistance. For many patients, it has simply been wherever the prescribing physician's office called it in.

As the home delivery pharmacy model matures and its cost advantages become more widely understood, that calculus is shifting. The question is no longer only whether a medication is covered — but whether the system delivering it is working in the patient's financial interest.

At MedDelivered, the answer to that question is built into the model itself.